Dicot Pharma Past Earnings Performance

Past criteria checks 0/6

Dicot Pharma's earnings have been declining at an average annual rate of -27.6%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually. Revenues have been declining at an average rate of 74.5% per year.

Key information

-27.6%

Earnings growth rate

52.8%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-74.5%
Return on equity-291.9%
Net Marginn/a
Next Earnings Update31 Oct 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Dicot Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:KN0 Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-51520
31 Mar 240-48490
31 Dec 230-44450
30 Sep 230-37370
30 Jun 230-34340
31 Mar 230-32320
31 Dec 220-32320
30 Sep 220-32310
30 Jun 220-31310
31 Mar 220-28280
31 Dec 210-27270
30 Sep 210-23230
30 Jun 210-22220
31 Mar 210-19190
31 Dec 200-18180
30 Sep 201-17260
30 Jun 201-16230
31 Mar 201-16170
31 Dec 191-13140
30 Sep 190-1240
30 Jun 190-1050
31 Mar 190-10100
31 Dec 180-670
30 Sep 180-670
30 Jun 180-450
31 Mar 180-230
31 Dec 170-220
31 Dec 160000

Quality Earnings: KN0 is currently unprofitable.

Growing Profit Margin: KN0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: KN0 is unprofitable, and losses have increased over the past 5 years at a rate of 27.6% per year.

Accelerating Growth: Unable to compare KN0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KN0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).


Return on Equity

High ROE: KN0 has a negative Return on Equity (-291.91%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies